Cite
HARVARD Citation
Long, G. et al. (n.d.). 24LBA Safety data from the phase 1b part of the MASTERKEY-265 study combining talimogene laherparepvec (T-VEC) and pembrolizumab for unresectable stage IIIB-IV melanoma. European journal of cancer. pp. S722-. [Online].